Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE versus OTOBIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE versus OTOBIONE.
HYDROCORTISONE vs OTOBIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a glucocorticoid that binds to the glucocorticoid receptor (GR), leading to altered gene expression. This results in anti-inflammatory, immunosuppressive, anti-proliferative, and vasoconstrictive effects. It also modulates carbohydrate, protein, and lipid metabolism.
OTOBIONE is a combination product containing ciprofloxacin (a fluoroquinolone antibiotic) and fluocinolone acetonide (a corticosteroid). Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, leading to bacterial cell death. Fluocinolone acetonide suppresses inflammation by binding to glucocorticoid receptors, inhibiting phospholipase A2, and reducing prostaglandin and leukotriene synthesis.
Oral: 10-20 mg every 6-8 hours; IV/IM: 100-500 mg every 2-6 hours for acute conditions; typical maintenance: 20-240 mg/day divided every 8-12 hours.
1-2 drops in affected ear(s) twice daily; otic administration only.
None Documented
None Documented
Clinical Note
moderateHydrocortisone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gatifloxacin."
Clinical Note
moderateHydrocortisone + Rosoxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rosoxacin."
Clinical Note
moderateHydrocortisone + Levofloxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Levofloxacin."
Clinical Note
moderateTerminal half-life: 1.5–2 hours (plasma). In tissues, biologic half-life is 8–12 hours due to intracellular activity. Half-life prolonged in hepatic impairment.
2.5 hours (prolonged to 12-24 hours in renal impairment, CrCl <30 mL/min)
Renal: primarily as inactive metabolites (cortisone, tetrahydrocortisone) and unchanged drug (<1%). Biliary/fecal: minimal (<5%).
Renal: 90% unchanged; biliary: <5% as metabolites; fecal: <2%
Category D/X
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid
Hydrocortisone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trovafloxacin."